<div class="p4l_caption"><div class="p4l_captionTitle"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4279394/" ref="ordinalpos=3755&amp;ncbi_uid=7040918&amp;link_uid=PMC4279394" image-link="/pmc/articles/PMC4279394/figure/F5/" class="imagepopup">Figure 5. SOX10 suppresses Wnt <span class="highlight" style="background-color:">signaling</span> via compete with TCF4 to bind β-catenin.  From: SOX10, a novel HMG-box-containing tumor suppressor, inhibits growth and metastasis of digestive cancers by suppressing the Wnt/β-catenin <span class="highlight" style="background-color:">pathway</span>. </a></div><br /><div class="p4l_captionBody">Inhibition of TCF activity (A) and CCND1, c-Myc and MMP7 promoter reporter activities (B) in SOX10-expressing tumor cells in a dose-dependent manner. *: p&lt;0.05, **: p&lt;0.01. qRT-PCR (C) and western blot (D) showed ectopic expression of SOX10 disrupted Wnt signaling pathway. (E) Co-immunoprecipitation (Co-IP) assays showing that exogenous V5-SOX10 binds endogenous β-catenin and vice versa. IP antibody or IgG negative control was used as indicated. (F) GST pull-down assay was performed with GST-β-catenin fusion protein or GST and V5-SOX10 as indicated.</div></div>